Ran Nussbaum - 25 Mar 2021 Form 4/A - Amendment Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
25 Mar 2021
Net transactions value
+$5,150
Form type
4/A - Amendment
Filing time
09 Jun 2021, 13:46:26 UTC
Date Of Original Report
22 Apr 2021
Previous filing
30 Nov 2022
Next filing
17 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise $5,150 +1,030 +0.07% $5.00* 1,431,717 25 Mar 2021 Managing Partner of entities affiliated with Pontifax Management III G.P. ( F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Options Exercise $0 -1,030 -100% $0.000000* 0 25 Mar 2021 Ordinary Shares 1,030 $5.00 By Pontifax Cayman III Limited Partnership F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 22, 2021, the reporting person filed a Form 4 that mistakenly listed the transaction date as March 24, 2021.